
Frequency Therapeutics FREQ
Annual report 2025
added 03-12-2026
Frequency Therapeutics Interest Expense 2011-2026 | FREQ
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Frequency Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.23 M | 8.47 M | 3.39 M | 976 K | 764 K | - | 1.78 M | -106 K | -174 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.47 M | -174 K | 2.54 M |
Quarterly Interest Expense Frequency Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.18 M | 1.43 M | 1.63 M | - | 2.28 M | 2.33 M | 1.91 M | - | 656 K | 786 K | 481 K | - | 263 K | 208 K | 178 K | - | 182 K | 182 K | 218 K | - | - | - | - | - | - | - | - | - | 63 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.33 M | 63 K | 874 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
BioLineRx Ltd.
BLRX
|
9.07 M | $ 2.25 | 1.81 % | $ 908 M | ||
|
BioNTech SE
BNTX
|
14.2 M | $ 91.28 | 0.11 % | $ 27.2 B | ||
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
5.2 M | $ 330.34 | 3.6 % | $ 43.3 B | ||
|
I-Mab
IMAB
|
722 K | - | - | $ 866 M | ||
|
Genfit SA
GNFT
|
4.68 M | - | 2.54 % | $ 160 B | ||
|
Catalyst Pharmaceuticals
CPRX
|
25.7 M | $ 24.98 | 1.17 % | $ 3.05 B | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
1.24 M | $ 10.14 | -0.29 % | $ 135 M | ||
|
Cardiff Oncology
CRDF
|
5 K | $ 1.58 | - | $ 106 M | ||
|
Curis
CRIS
|
890 K | $ 0.53 | -3.07 % | $ 6.98 M | ||
|
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | ||
|
Crinetics Pharmaceuticals
CRNX
|
-357 K | $ 37.7 | 1.26 % | $ 3.55 B | ||
|
CRISPR Therapeutics AG
CRSP
|
86.6 M | $ 49.15 | -0.73 % | $ 4.42 B | ||
|
Adverum Biotechnologies
ADVM
|
8.23 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
4.68 M | $ 2.96 | -1.0 % | $ 252 M | ||
|
Applied Molecular Transport
AMTI
|
-4 K | - | - | $ 10.1 M | ||
|
AgeX Therapeutics
AGE
|
51 K | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | ||
|
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | ||
|
CytomX Therapeutics
CTMX
|
28 K | $ 4.4 | -3.51 % | $ 607 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
Citius Pharmaceuticals
CTXR
|
10.8 K | $ 0.86 | 0.67 % | $ 5.79 M | ||
|
Cue Biopharma
CUE
|
100 K | $ 0.18 | -1.61 % | $ 17.1 M | ||
|
Allena Pharmaceuticals
ALNA
|
-38 K | - | 3.16 % | $ 1.9 M | ||
|
Alpine Immune Sciences
ALPN
|
476 K | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | ||
|
Aquestive Therapeutics
AQST
|
6.55 M | $ 4.09 | -0.97 % | $ 437 M | ||
|
Daré Bioscience
DARE
|
-153 K | $ 1.81 | 4.02 % | $ 20.2 M | ||
|
Aravive
ARAV
|
2.84 M | - | -13.39 % | $ 1.45 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
10.1 M | $ 8.22 | 2.37 % | $ 225 M | ||
|
Aptinyx
APTX
|
737 K | - | -39.0 % | $ 4.57 M | ||
|
Dyadic International
DYAI
|
250 K | $ 0.87 | -2.8 % | $ 31.5 M | ||
|
Celldex Therapeutics
CLDX
|
927 K | $ 31.37 | 1.0 % | $ 2.08 B | ||
|
Avenue Therapeutics
ATXI
|
294 K | - | -52.27 % | $ 4.45 M |